GLP-1 agonists include semaglutide, exenatide, and liraglutide, which quickly became popular due to their ability to promote weight loss, making them effective in also managing hyperglycemia and obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.